Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

DFB Healthcare Acquisitions Corp. Closes $250 Million Initial Public Offering

NEW YORK, Feb. 21, 2018 /PRNewswire/ — DFB Healthcare Acquisitions Corp. (NASDAQ: DFBHU) (“DFB Healthcare”) announced today that it closed its initial public offering of 25,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds of $250,000,000.

The Company’s units began trading on the NASDAQ Capital Market under the ticker symbol “DFBHU” on February 16, 2018. Each unit consists of one share of the Company’s common stock and one-third of one warrant, each whole warrant enabling the holder thereof to purchase one share of common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the common stock and warrants are expected to be listed on the NASDAQ Capital Market under the ticker symbols “DFBH” and “DFBHW”, respectively.

DFB Healthcare is sponsored by Deerfield/RAB Ventures, LLC, which was jointly founded by Deerfield Management Company L.P. (“Deerfield”) and DFB Healthcare’s management team, led by CEO Richard Barasch. Deerfield is an investment firm focused exclusively on the healthcare industry, and its investment activity spans both public and private securities. Mr. Barasch has more than 30 years of experience in healthcare services, health insurance, and related industries, and was CEO of Universal American Corp. from 1995 until the Company’s acquisition by WellCare Health Plans in April 2017.

Goldman Sachs & Co. and Deutsche Bank Securities acted as joint book runners for the offering and Leerink Partners acted as co-manager. DFB Healthcare has granted the underwriters a 45-day option to purchase up to an additional 3,750,000 units at the initial public offering price to cover overallotments, if any.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission on February 15, 2018. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The registration statement can be obtained at www.sec.gov.

About DFB Healthcare Acquisitions Corp.

DFB Healthcare Acquisitions Corp. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It has not identified any business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with respect to identifying any business combination target. Its acquisition and value creation strategy will be to identify and acquire a business in the healthcare sector.

The offering was made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone toll-free at 1-866-471-2526 or by email at [email protected], from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, New York 10005-2836 (Tel: (800) 503-4611; Email: [email protected]), and from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525, ext. 6132 or by email at [email protected].

Contact

DFB Healthcare Acquisitions Corp.
Chris Wolfe, (212) 965-2400
[email protected]